DK1611238T3 - Modulatoriske glutamattransportforbindelser og -fremgangsmåder - Google Patents
Modulatoriske glutamattransportforbindelser og -fremgangsmåderInfo
- Publication number
- DK1611238T3 DK1611238T3 DK04714617T DK04714617T DK1611238T3 DK 1611238 T3 DK1611238 T3 DK 1611238T3 DK 04714617 T DK04714617 T DK 04714617T DK 04714617 T DK04714617 T DK 04714617T DK 1611238 T3 DK1611238 T3 DK 1611238T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- modulatory
- transport compounds
- glutamate transport
- protein expression
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Psychology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45022703P | 2003-02-26 | 2003-02-26 | |
PCT/US2004/005698 WO2004076675A2 (en) | 2003-02-26 | 2004-02-25 | Glutamate transport modulatory compounds and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1611238T3 true DK1611238T3 (da) | 2009-10-26 |
Family
ID=32927622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04714617T DK1611238T3 (da) | 2003-02-26 | 2004-02-25 | Modulatoriske glutamattransportforbindelser og -fremgangsmåder |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060121488A1 (da) |
EP (1) | EP1611238B1 (da) |
JP (1) | JP2006524637A (da) |
KR (1) | KR20050115245A (da) |
AT (1) | ATE433993T1 (da) |
AU (1) | AU2004214938B2 (da) |
CA (1) | CA2516619A1 (da) |
DE (1) | DE602004021574D1 (da) |
DK (1) | DK1611238T3 (da) |
ES (1) | ES2328811T3 (da) |
MX (1) | MXPA05009134A (da) |
PL (1) | PL377896A1 (da) |
WO (1) | WO2004076675A2 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE540129T1 (de) * | 2002-11-22 | 2012-01-15 | Univ Johns Hopkins | Target zur therapie kognitiver behinderungen |
EP1680126A4 (en) * | 2003-10-21 | 2009-05-13 | Univ Johns Hopkins | NEUROPROTEKTION WITH BETA-LACTAM COMPOUNDS |
EP1861107A2 (en) * | 2005-03-04 | 2007-12-05 | Alsgen, Inc. | Treatment of amyotrophic lateral sclerosis with norethindrone and analogues |
PT2982372T (pt) | 2005-04-05 | 2020-10-09 | Univ Yale | Agentes moduladores do glutamato no tratamento de distúrbios mentais |
WO2007098047A2 (en) * | 2006-02-16 | 2007-08-30 | The Mclean Hospital Corporation | Methods and compositions for the treatment of parkinson's disease |
FR2902010B1 (fr) * | 2006-06-12 | 2008-08-22 | Pierre Fabre Medicament Sa | Utilisation de la 1,7 dimethylxanthine pour la fabrication d'un medicament psychoanaleptique non anxiogene destine au traitement d'un trouble neuropsychiatrique |
WO2009033055A1 (en) * | 2007-09-06 | 2009-03-12 | Rutgers, The State University Of New Jersey | Methods and kits for identification of anti-excitotoxic compounds |
WO2009096612A1 (en) * | 2008-01-30 | 2009-08-06 | Korea Institute Of Science And Technology | Regulation of neutrotransmittter release through anion channels |
WO2011099502A1 (ja) * | 2010-02-10 | 2011-08-18 | 公立大学法人横浜市立大学 | 神経選択的転写抑制因子NRSFに特異的に結合するmSin3B に結合する化合物の利用 |
FR2958664B1 (fr) | 2010-04-07 | 2012-10-26 | Coatex Sas | Utilisation d'un latex de styrene et de taille de 100 nm comme agent rheologique dans une sauce de couchage papetiere, sauce et son procede d'obtention |
KR101351181B1 (ko) | 2010-05-11 | 2014-01-14 | 가천대학교 산학협력단 | 단핵식세포계 세포 내에서 age-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법 |
US20130303562A1 (en) * | 2010-12-02 | 2013-11-14 | Massachusetts Institute Of Technology | Chemical and rnai suppressors of neurotoxicity in huntington's disease |
WO2014076702A1 (en) * | 2012-11-14 | 2014-05-22 | Ramot At Tel-Aviv University Ltd. | Combination treatment for amyotrophic lateral sclerosis (als) |
US10448861B2 (en) * | 2013-09-06 | 2019-10-22 | Covidien Lp | System and method for light based lung visualization |
CN104074095A (zh) * | 2014-06-25 | 2014-10-01 | 宁波天源科技有限公司 | 流变改质剂 |
KR101809379B1 (ko) * | 2016-10-13 | 2017-12-14 | 연세대학교 산학협력단 | 디오스민 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 근육 질환 예방 또는 치료용 조성물 |
CN111116374B (zh) * | 2019-12-04 | 2020-12-15 | 北京理工大学 | 一种氨鲁米特与2-硝基苯甲酸合成π-π键共晶体的方法 |
CN110923148B (zh) * | 2019-12-11 | 2021-05-14 | 华北制药股份有限公司 | 青霉素v钾高产菌及其在发酵生产青霉素v钾中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4575506A (en) * | 1983-11-03 | 1986-03-11 | Zambon S.P.A. | Method of treatment for inhibiting the tolerance onset while treating painful syndromes with central analgesics |
US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
DE69118700D1 (de) * | 1990-08-13 | 1996-05-15 | Searle & Co | Verwendung von heterozyklischen aminoalkoholverbindungen zur herstellung eines medikaments für die behandlung von erkrankungen des zns |
US5658782A (en) * | 1993-10-20 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization | Amino acid transporters and uses |
US5795563A (en) * | 1996-09-04 | 1998-08-18 | Sphingomonas Research Partners, L.P. | Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment |
US6255467B1 (en) * | 1997-11-06 | 2001-07-03 | Pathobiotek Diagnostics Inc. | Human blood bacterium |
US7060457B2 (en) * | 1998-03-18 | 2006-06-13 | Johns Hopkins University | Aberrant glutamate transporters and methods of use |
CA2332272A1 (en) * | 1998-05-15 | 1999-11-25 | University Of Vermont | Novel analogs of 16-hydroxyeicosatetraenoic acid |
EP2305251A3 (en) * | 1999-08-16 | 2011-05-18 | Revaax Pharmaceuticals LLC | Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of sexual disorder |
US6489319B2 (en) * | 1999-08-16 | 2002-12-03 | Revaax Pharmaceuticals, Llc | Neurotherapeutic use of carboxypeptidase inhibitors |
US6426342B2 (en) * | 1999-08-16 | 2002-07-30 | Revaax Pharmaceuticals, Llc | Use of β-lactamase inhibitors as neuroprotectants |
US20020013270A1 (en) * | 2000-06-05 | 2002-01-31 | Bolte Ellen R. | Method for treating a mental disorder |
US6248360B1 (en) * | 2000-06-21 | 2001-06-19 | International Health Management Associates, Inc. | Complexes to improve oral absorption of poorly absorbable antibiotics |
AU2001288792A1 (en) * | 2000-09-06 | 2002-03-22 | Neurotherapeutics, Llc | Method of treating neurologic disorders |
US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
DE60325695D1 (de) * | 2002-02-15 | 2009-02-26 | Univ Johns Hopkins | Der eaat2-promotor und dessen verwendung |
ATE540129T1 (de) * | 2002-11-22 | 2012-01-15 | Univ Johns Hopkins | Target zur therapie kognitiver behinderungen |
-
2004
- 2004-02-25 DK DK04714617T patent/DK1611238T3/da active
- 2004-02-25 MX MXPA05009134A patent/MXPA05009134A/es active IP Right Grant
- 2004-02-25 AT AT04714617T patent/ATE433993T1/de not_active IP Right Cessation
- 2004-02-25 JP JP2006503879A patent/JP2006524637A/ja active Pending
- 2004-02-25 ES ES04714617T patent/ES2328811T3/es not_active Expired - Lifetime
- 2004-02-25 PL PL377896A patent/PL377896A1/pl not_active Application Discontinuation
- 2004-02-25 US US10/546,860 patent/US20060121488A1/en not_active Abandoned
- 2004-02-25 DE DE602004021574T patent/DE602004021574D1/de not_active Expired - Lifetime
- 2004-02-25 WO PCT/US2004/005698 patent/WO2004076675A2/en active Application Filing
- 2004-02-25 AU AU2004214938A patent/AU2004214938B2/en not_active Ceased
- 2004-02-25 CA CA002516619A patent/CA2516619A1/en not_active Abandoned
- 2004-02-25 KR KR1020057015591A patent/KR20050115245A/ko not_active Withdrawn
- 2004-02-25 EP EP04714617A patent/EP1611238B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2006524637A (ja) | 2006-11-02 |
CA2516619A1 (en) | 2004-09-10 |
EP1611238B1 (en) | 2009-06-17 |
AU2004214938A1 (en) | 2004-09-10 |
MXPA05009134A (es) | 2005-12-05 |
ES2328811T3 (es) | 2009-11-18 |
KR20050115245A (ko) | 2005-12-07 |
EP1611238A4 (en) | 2007-07-04 |
AU2004214938B2 (en) | 2008-11-06 |
US20060121488A1 (en) | 2006-06-08 |
WO2004076675A2 (en) | 2004-09-10 |
DE602004021574D1 (de) | 2009-07-30 |
WO2004076675A3 (en) | 2005-03-17 |
PL377896A1 (pl) | 2006-02-20 |
EP1611238A2 (en) | 2006-01-04 |
ATE433993T1 (de) | 2009-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1611238T3 (da) | Modulatoriske glutamattransportforbindelser og -fremgangsmåder | |
ATE482972T1 (de) | Tgf-beta1-bindende und geträgerte peptide | |
CY1121687T1 (el) | Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων | |
CY1110923T1 (el) | Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων | |
BRPI0713421A2 (pt) | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero | |
CY1113243T1 (el) | Μεθοδοι θεραπειας με χρηση αντισωματων cτlα-4 | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
DK1957061T3 (da) | Kombination omfattende mindst én aminosyre og en PKR-inhibitor til anvendelse i behandlingen af muskelsvind | |
RS53215B (en) | NEUTRAL ANTIBODIES HAVING SPECIFICITY TO HUMAN IL-17 | |
CY1115745T1 (el) | Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου | |
EA201490735A1 (ru) | Лечение дегенеративного заболевания сустава | |
CY1108297T1 (el) | Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
CY1112330T1 (el) | Πρωτεϊνες συνδεσης gag | |
ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
ATE440860T1 (de) | An proteinphosphatase 2a bindende synthetische oder natürliche peptide, identifikationsverfahren und anwendungen | |
NO20080609L (no) | Systemer og fremgangsmater for separering av proteiner fra bindevev | |
CY1110381T1 (el) | Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων | |
CY1105380T1 (el) | Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων | |
MXPA03000316A (es) | Reactivos y metodos para la identificacion de agentes de enlace. | |
ATE504602T1 (de) | Für humane matriptase spezifische bindungsproteine | |
EA200600042A1 (ru) | Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах | |
ES2507094T3 (es) | Proteína específica del timo | |
SE0302559D0 (sv) | Method | |
ATE534902T1 (de) | Replikationsproteinn ciz1 | |
BR112023002234A2 (pt) | Anticorpos sars-cov-2 para tratamento e prevenção de covid-19 |